[{"orgOrder":0,"company":"Vaxxas","sponsor":"Bill & Melinda Gates Foundation ","pharmaFlowCategory":"D","amount":"$5.0 million ","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Awarded US$5 million [AU$7.5 million] Grant for Clinical Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas\u2019 Novel High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Vaxxas","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vaxxas","sponsor":"OneVentures","pharmaFlowCategory":"D","amount":"$23.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Raises US$23 Million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Vaxxas","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Awarded US$3.67 Million (AU$5.4 million) from Global Charitable Foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination Using Needle-Free Vaccine Patch","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Vaxxas","sponsor":"SK Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SK Bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Vaxxas
Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology.
The funding will support the IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
HexaPro, a second-generation version of the spike protein used in all major U.S. approved COVID-19 vaccines, which was modified to be more stable and immunogenic than its predecessor, giving potential coverage of all known SARS-CoV-2 variants.
The vaccine being delivered by the Vaxxas HD-MAP in this Phase I clinical trial is a commercially available seasonal flu vaccine (IIV4) targeting four significant strains of the influenza virus.
Lead Product(s):
Inactivated Seasonal Influenza Vaccine Quadrivalent
The financing will accelerate the clinical program for Vaxxas’ COVID-19 vaccine patch candidate which is based upon the company’s proprietary HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved COVID-19 vaccines.
HexaPro, a highly stabilized protein that is designed to mimic the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognize and fight SARS-CoV-2 infection.
The license obtained by Vaxxas from the United States’ National Institutes of Health, enables Vaxxas to create the first needle-free, room-temperature stable, SARS-CoV-2 spike subunit vaccine (HexaPro) patch to enter clinical studies.
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model.
Under the collaboration agreement, originally signed in 2012, through the exercise of this option MSD gains exclusive worldwide rights to develop and commercialize an undisclosed vaccine utilizing Vaxxas’ HD-MAP technology.
The new funding will be used for IND-enabling studies and a first-in-human clinical study for measles and rubella vaccination using Vaxxas’ advanced HD-MAP platform.